MXC: $0.024
What We Do

MGC Pharma implementing a “Seed to Medicine” core strategy. MGC currently holds pipelines for phytocannabinoid-based medications and unique formulations (Phytomedicines), both proprietary and for third parties, all under GMP certified regulations and facilities. This includes our ability to create API (Active Pharmaceutical Ingredient) of various phytocannabinoids alongside compounding to be used in the pharmaceutical treatment and research globally.

MGC Pharma is continuously creating worth for investors through its clear vision, tactical joint ventures and over 40 years’ collective experience in the cannabis for medicinal purposes industry.